The report “North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) Forecasts to 2017”, the North American market was valued at $66.7 billion in 2012 and is poised to reach $102.2 billion by 2017. The U.S. registered a higher market share, valued at $59.3 billion in 2012 and is expected to grow at a high single digit CAGR from 2012 to 2017. The Canadian market is also growing at a decent CAGR of 7.9%, to reach $10.7 billion by 2017.
Pune, India -- (SBWIRE) -- 10/28/2015 -- Browse 95 market data tables with 28 figures spread through 267 pages and in-depth TOC on "North American Drug Delivery Technologies Market"
Early buyers will receive 10% customization on this report.
This report studies the North American Drug Delivery Technologies Market over the forecast period of 2012 - 2017.
The U.S. Supreme courts' decision to uphold the healthcare reforms is expected to substantially increase the number of insured citizens in the U.S. This will thereby boost the market for novel drug delivery technology based formulations and devices. In addition, the rising number of drug approvals by Health Canada, serves as an opportunity for the Canadian market.
The acquisitions of Eurand Pharmaceuticals (Netherlands) by Aptalis Pharma(U.S.), Labopharm (Canada) by Paladin Labs (Canada), and CIMA Labs (U.S.) and Cephalon by Teva Pharmaceuticals (Israel) constitute the major developments in the North American market.
Get The Sample Copy Of This Report: http://www.marketsandmarkets.com/requestsample.asp?id=1209
Also, there are significant developments in the field of targeted drug delivery (using liposomes and nanoparticle drug carriers) owing to the advancements in polymers and biopolymers technology for small molecules, macromolecules, and prodrugs.
The growth of the market is driven by the increasing adoption of drug delivery technologies by pharmaceutical and medical device companies in North America, and greater patient acceptability of drug delivery products. The opportunities for the growth of this market include developments of drug deliverytechnologies for non-conventional therapeutic applications and for use in home setting. Other factors like collaborations of drug delivery firms with pharmaceutical firms also offer opportunities to the drug delivery firms, as they could assist pharmaceutical companies with their manufacturing services technology platforms, product development, and regulatory procedures. However, in the past and present, product recalls of drug delivery products is one factor that hampered the growth of this market and also raised concerns on R&D expenditure for development of such products.
This research report categorizes the North American drug delivery technologies market by routes of administration; it includes oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal technologies. All these market segments are further divided into sub-segments that comprise of formulations or devices, to provide exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. The North American market for oral drug delivery technologies was estimated at $25.4 billion in 2012 and is expected to grow at a healthy CAGR of 8.6% from 2012 to 2017. Oral technologies offer easier and cost-effective reformulation strategies; hence they occupy the largest share in the market. On the other hand, pulmonary technologies market is expected to grow at the highest CAGR of 11.8%, due to the increased adoption rates of pulmonary devices and their expanding applications. This market is poised to reach $23.1 billion by 2017.
Contact Our Research Analysts for More Information@
Key players in the market are 3M Company (U.S.), Aptalis Pharma, Inc. (U.S.), Baxter International, Inc. (U.S.), Becton Dickinson & Co. (U.S.), Catalent Pharma Solutions (U.S.), Cipher Pharmaceuticals (Canada), Dow Chemical Company (U.S.), Endo Pharmaceuticals (U.S.), Johnson & Johnson (U.S.), Nektar Therapeutics (U.S.), OptiNose (U.S.), QLT (Canada), and Valeant Pharmaceuticals (Canada).
MarketsandMarkets is world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Subscribe Reports from Healthcare Domain @ http://www.marketsandmarkets.com/Subscription.html
Unit No. 802, 8th Floor,
Tower - 7, Magarpatta City SEZ,
Hadapsar, Pune – 411013,
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets